Latest news with #DerekO'Leary
Mid East Info
22-04-2025
- Business
- Mid East Info
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches - Middle East Business News and Information
Number of patients reached in 2024 jumps 8% to 66 million. In 2024, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 855 million, reflecting a 17% increase compared to the previous year. R&D investments rise to EUR 6.2 billion, 23.2% of group net sales. Company prepares new product launches starting in 2025. Dubai, United Arab Emirates: Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion. 'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.' Strong Growth in IMETA: In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year. Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.' Human Pharma: investing in existing products and new launches Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion. The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales. 'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.' After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients. Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval. Animal Health: rapid response against transboundary animal diseases Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion. Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply. Sustainable Development: Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs. As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date. Outlook: The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects. * sales growth numbers are adjusted for currency effects **one-sided p-value from a z-test of the null hypothesis ORR ≤30% Boehringer Ingelheim: Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.
Web Release
22-04-2025
- Business
- Web Release
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion. 'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.' Strong Growth in IMETA In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year. Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.' Human Pharma: investing in existing products and new launches Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion. The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales. 'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.' After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients. Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval. Animal Health: rapid response against transboundary animal diseases Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion. Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply. Sustainable Development Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs. As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date. Outlook The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects. * sales growth numbers are adjusted for currency effects **one-sided p-value from a z-test of the null hypothesis ORR ?30% Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim – Life Forward | Boehringer Ingelheim.
Zawya
22-04-2025
- Business
- Zawya
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
In 2024, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 855 million, reflecting a 17% increase compared to the previous year. R&D investments rise to EUR 6.2 billion, 23.2% of group net sales. Company prepares new product launches starting in 2025. Dubai, United Arab Emirates – Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion. 'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.' Strong Growth in IMETA In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year. Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.' Human Pharma: investing in existing products and new launches Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion. The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales. 'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.' After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients. Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval. Animal Health: rapid response against transboundary animal diseases Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion. Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply. Sustainable Development Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs. As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date. Outlook The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects. * sales growth numbers are adjusted for currency effects **one-sided p-value from a z-test of the null hypothesis ORR ≤30% About Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim - Life Forward | Boehringer Ingelheim.
Zawya
25-02-2025
- Health
- Zawya
Dubai Miracle Garden blooms with hope as Boehringer Ingelheim concludes Interstitial Lung Disease Awareness campaign
Interstitial Lung Disease (ILD) is an umbrella term used for a large group of diseases that cause scarring (fibrosis) of the lungs. The scarring causes stiffness in the lungs which makes it difficult to breathe and get oxygen to the bloodstream. [i] Boehringer Ingelheim, in collaboration with Emirates Thoracic Society (ETS) and social media influencer Ghaith Marwan, unveiled a breathtaking installation of lungs made from flowers at the Dubai Miracle Garden to raise awareness of the disease and highlight the importance of early diagnosis. In the run-up to the event, a public social media campaign, led by Boehringer Ingelheim, achieved the collective goal of 1 million steps to increase the impact of the campaign. Dubai, United Arab Emirates: Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has collaborated with Emirates Thoracic Society (ETS) and social media influencer Ghaith Marwan, to raise awareness of Interstitial Lung Disease (ILD) through a community engagement initiative achieving 1 million steps and culminating in a breathtaking installation unveiling at Dubai Miracle Garden on 22 February 2025. ILD is an umbrella term used for several diseases that cause scarring, or fibrosis, of the lungs. The scarring causes stiffness in the lungs which makes it difficult to breathe and deliver oxygen to the bloodstream. Lung damage from ILDs is often irreversible and progresses over time. Common symptoms of ILD are shortness of breath, consistent dry cough, chest discomfort, fatigue and occasionally weight loss.i Early diagnosis and treatment of many ILD diseases, such as Idiopathic pulmonary fibrosis (IPF), can slow disease progression and preserve quality of life for patients [ii]. Under the theme 'Think Lungs', the social media campaign encouraged the public to share their breathtaking moments together with their daily step count to reach the collective goal of one million steps. The campaign concluded at the Dubai Miracle Garden in the presence of ETS representatives, renowned pulmonologists, Boehringer Ingelheim representatives and Ghaith Marwan. The event saw the unveiling of a 5-meter lung installation made entirely of colorful and blossoming flowers. Following the event, in line with Boehringer Ingelheim's commitment to sustainability, the flowers from the installation were gifted to Rashid Centre For People of Determination. Derek O'Leary, Regional Managing Director, Boehringer Ingelheim in India, Middle East, Turkey and Africa, said: 'Lung health shouldn't be an afterthought—it should be a priority. At Boehringer Ingelheim, we launched Think Lungs to spark a movement, because awareness leads to action, and action can improve lives. Seeing people come together to join our 1 Million step for ILD awareness movement and stand before the lung installation at Dubai's Miracle Garden was a powerful reminder of what's possible when people come together for a cause. Our vision is a future where early diagnosis is the norm, individuals take charge of their lung health, and communities replace stigma with support and hope.' Dr. Bassam Mahboub, Head of the Pulmonology, Department at Rashid Hospital and Vice President of the Emirates Thoracic Society, said, 'Diagnosing ILD can be a challenge given the shared symptoms with other lung diseases [iii] and delays in treatment can hinder efforts to improve outcomesii. It is encouraging to see key healthcare stakeholders come together with a shared vision to raise public awareness of lung diseases which are often overlooked. Awareness campaigns like 'Think Lungs', empower communities to seek expert opinions early and to ask their physicians the right questions which can potentially lead to earlier diagnosis and better treatment outcomes.' The campaign highlighted the need for proactive attention to lung health, encouraging individuals to recognize symptoms and seek timely medical advice. Through this initiative, Boehringer Ingelheim aims to inspire behavioral change, highlight the power of early detection, and unite communities in a shared commitment to lung health. Boehringer Ingelheim is dedicated to improving the lives of patients affected by ILDs through ongoing research, development and strategic collaborations. As part of its commitment to improve the lives of patients affected by ILDs, Boehringer Ingelheim has developed an educational website called Life With Pulmonary Fibrosis, available in both English and Arabic providing patients with information about their condition and offering ways to enhance their mental and physical well-being. About Boehringer Ingelheim Boehringer Ingelheim Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at For more information, please contact: Sayali Kavalekar Manager, Human Pharma Communications, Corporate Affairs, India, Middle East, Turkey, and Africa (IMETA) Boehringer Ingelheim Email: [i] American Lung Association. (n.d.). Interstitial lung disease (ILD). [ii] Alsomali, H., Palmer, E., Aujayeb, A., & Funston, W. (2023). Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review. Pulmonary therapy, 9(2), 177–193. [iii] Breathing Matters. (n.d.). Other interstitial lung diseases (ILDs).
